Citations

Clear

512 citation(s) found for "Turner, ST".

Adiposity, Change in Adiposity, and Cognitive Decline in Mid‐ and Late Life
West, Nancy A., Lirette, Seth T. , Cannon, Victoria , Windham, B. Gwen , Turner, Stephen T. , Mosley, Thomas H. , Lirette, Seth

Mayo Clinic

Journal of the American Geriatrics Society | March 1, 2017 | Volume: 65 | Issue: 6 | Pages: 1282-1288

10.1111/jgs.14786 | PMID 28248413 Get It

Objectives To examine associations between adiposity and adiposity change (loss, stable, gain) and subsequent longitudinal cognitive performance in African Americans in mid and late life. Design Cohort study using linear mixed models. Setting Genetic Epidemiology Network of Arteriopathy. Participants African‐American sibships with hypertension in Jackson, Mississippi (N = 1,108). Measurements Waist circumference and body mass index ( BMI ) were measured at two examinations 5 years apart. Stable adiposity was defined as values within 5% of the first measure. A composite cognitive Z ‐score was derived from individual cognitive test Z ‐scores at two study visits 6 years apart. Results Larger waist circumference was associated with greater rate of cognitive decline during follow‐up (beta = −0.0009 per year, P = .001); BMI , change in waist circumference, and change in BMI were not associated with rate of decline. Loss of adiposity in midlife was associated with higher cognitive Z ‐scores in middle‐aged individuals, and loss of adiposity in late life was associated with lower Z ‐scores in older adults ( P = .01 for interaction between waist circumference and age; P = .04 for interaction between BMI and age). Simultaneous inclusion of waist circumference and BMI in the cross‐sectional model suggested an association between larger waist circumference and poorer cognitive performance (beta = −0.009, P = .006) and between higher BMI and better cognitive performance (beta = 0.014, P = .06). Conclusion The results suggested a differential pattern of the relationship between adiposity and cognition according to age (mid‐ or late life) and regional distribution of adiposity.
Locked Fracture Dislocation of the Calcaneus Treated with Minimal Open Reduction and Percutaneous Fixation: A Report of Two Cases and Review of the Literature
Turner, Norman S. , Haidukewych, George J.

Mayo Clinic

Foot & Ankle International | January 13, 2017 | Volume: 24 | Issue: 10 | Pages: 796-800

10.1177/107110070302401012 | PMID 14587997 Get It

Fractures of the calcaneus with associated locked dislocation of the posterior facet have been previously described. Two patients with a calcaneal fracture with a locked dislocation of a portion of the posterior facet were treated with minimally invasive open reduction and percutaneous screw fixation of the fragment with cannulated screws. Both patients had satisfactory reductions and healed the fractures without any soft-tissue complications. This technique can be a useful addition to the armamentarium of the surgeon treating these injuries, especially in the patient at high risk for wound complications.
Treating Tobacco Use and Dependence in Kidney Transplant Recipients: Development and Implementation of a Program
Ehlers, Shawna L. , Patton, Pamela R., Lloyd-Turner, Joni, Howard, Richard J. , Rodrigue, James R. , Kaplan, Bruce

Mayo Clinic

Progress in Transplantation | January 13, 2017 | Volume: 16 | Issue: 1 | Pages: 33-37

10.1177/152692480601600108 | PMID 16676672 Get It

Tobacco use adversely affects transplant outcomes such as graft survival, patient survival, and other conditions that alter transplant patient longevity. Especially concerning is tobacco's relationship to cardiovascular disease, the number 1 cause of death in kidney transplant recipients. Many authors conclude that tobacco interventions ought to be provided to patients and sometimes lament that there are no tobacco dependence interventions designed for kidney transplant recipients. European Best Practice Guidelines for Renal Transplantation also support tobacco dependence interventions. The purpose of this article is to describe one institution's experience in implementing the clinical practice guideline for treating tobacco use and dependence within a kidney and pancreas transplant program.
The complex genetics of gait speed: genome-wide meta-analysis approach
Ben-Avraham, Dan, Karasik, David , Verghese, Joe , Lunetta, Kathryn L. , Smith, Jennifer A. , Eicher, John D., Vered, Rotem, Deelen, Joris , Arnold, Alice M. , Buchman, Aron S. , Faul, Jessica D. , Nethander, Maria , Fornage, Myriam , Adams, Hieab H.H. , Matteini, Amy M., Callisaya, Michele L. , Smith, Albert V. , Yu, Lei, Jager, Philip L. De , Evans, Denis A., Guðnason, Vilmundur , Hofman, Albert , Pattie, Alison, Knopman, Davis S., Parimi, Neeta, Bandinelli, Stefania , Beekman, Marian , Gutman, Danielle , Sharvit, Lital , Mooijaart, Simon P. , Liewald, David C. , Houwing‐Duistermaat, Jeanine J. , Ohlsson, Claes , Moed, Matthijs, Hernández, Dena , McWhirter, Rebekah , Thomson, Russell , Tranah, Gregory J. , Uitterlinden, André G. , Weir, David R. , Zhao, Wei , Starr, John M. , Johnson, Andrew D. , Bennett, David A. , Cummings, Steven R. , Deary, Ian J. , Harris, Tamara B., Kardia, Sharon L. R., Mosley, Thomas H. , Srikanth, Velandai , Windham, B. Gwen , Davies, Gail , Evans, Daniel S. , Ferrucci, Luigi , Atzmon, Gil , Bennett, David A. , Turner, Stephen T. , Tanaka, Toshiko , Corley, Janie , Launer, Lenore J. , Verlinden, Vincentius J.A. , Mellström, Dan , Geest, Jos N. van der , Karlsson, Magnus K , Liu, Ching‐Ti , Ikram, M. Arfan , Newman, Anne B. , Walston, Jeremy D , Slagboom, P. Eline , Kiel, Douglas P. , Murabito, Joanne M. , Smith, Jennifer A , Adams, Hieab H H , Smith, Albert V , Ferrucci, Luigi , Ohlsson, Claes , Srikanth, Velandai K

Mayo Clinic

Aging | December 30, 2016 | Volume: 9 | Issue: 1 | Pages: 209-246

10.18632/aging.101151 | PMID 28077804 Get It

SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function
Li, Man , Weeks, Olivia , Mijatovic, Vladan, Teumer, Alexander , Tromp, Gerard , Fuchsberger, Christian , Gorski, Mathias , Nutile, Teresa , Sedaghat, Sanaz , Sorice, Rossella , Arking, Dan E. , Bihlmeyer, Nathan A. , Böger, Carsten A., Carroll, Robert J. , Cornelis, Marilyn C., Faul, Jessica D. , Feitosa, Mary F. , Gambaro, Giovanni , Gasparini, Paolo , Giulianini, Franco, Heid, Iris M. , Huang, Jinyan , Imboden, Medea , Jeff, Janina M., Jhun, Min A., Katz, Ronit , Kifley, Annette , Kilpeläinen, Tuomas O. , Laakso, Markku , Li‐Gao, Ruifang , Lohman, Kurt, Lu, Yingchang , Mägi, Reedik , Mihailov, Evelin, Mohlke, Karen L. , Mook‐Kanamori, Dennis O. , Robino, Antonietta , Salvi, Erika , Schick, Ursula M., Schulz, Christina‐Alexandra , Smith, Albert V. , Traglia, Michela , Yerges-Armstrong, Laura M. , Goodarzi, Mark O. , Kraja, Aldi T., Wessel, Jennifer , Group,, CHARGE Glycemic-T2D Working, Group,, CHARGE Blood Pressure Working, Boerwinkle, Eric , Borecki, Ingrid B. , Bork‐Jensen, Jette , Böttinger, Erwin P. , Braga, Daniele , Brandslund, Ivan , Brody, Jennifer A. , Carey, David J. , Christensen, Cramer, Crook, Errol D., Boer, Ian H. de , Vries, Aiko P. J. de , Devuyst, Olivier , Dreisbach, Albert W. , Endlich, Karlhans , Franco, Oscar H. , Glümer, Charlotte , Gottesman, Omri, Grarup, Niels , Guðnason, Vilmundur , Harris, Tamara B., Hofman, Albert , Husemoen, Lise Lotte N. , Jackson, Rebecca D. , Jørgensen, Marit E. , Kähönen, Mika , Kardia, Sharon L. R., König, Wolfgang , Kriebel, Jennifer , Lauritzen, Torsten , Lehtimäki, Terho , Levy, Daniel , Linksted, Pamela , Loos, Ruth J. F. , Lupo, Antonio , Meisinger, Christine, Melander, Olle , Mitchell, Paul, Nauck, Matthias, Orho‐Melander, Marju , Parsa, Afshin, Pedersen, Oluf , Peters, Annette , Peters, Ulrike , Polašek, Ozren , Qi, Lu , Reiner, Alex P. , Rettig, Rainer, Ridker, Paul M., Rivadeneira, Fernando , Rossouw, Jacques E. , Schmidt, Frank , Soranzo, Nicole , Strauch, Konstantin , Toniolo, Daniela , Uitterlinden, André G. , Ulivi, Sheila , Velayutham, Dinesh , Völker, Uwe , Völzke, Henry , Waldenberger, Mélanie , Wang, Jie Jin , Weir, David R. , Witte, Daniel R. , Kuivaniemi, Helena , Fox, Caroline S., Franceschini, Nora , Goessling, Wolfram , Köttgen, Anna , Chu, Audrey Y., Rudan, Igor , Vasan, Ramachandran S. , Duijn, Cornelia M. van , Zhao, Wei , Padmanabhan, Sandosh , Lindgren, Cecilia M. , Franks, Paul W. , Weiß, Stefan , Langenberg, Claudia , Hattersley, Andrew T. , Turner, Stephen T. , Li, Yong , Huffman, Jennifer E. , Lyytikäinen, Leo‐Pekka , Tin, Adrienne , Yang, Qiong , Ahluwalia, Tarunveer S. , Chasman, Daniel I. , Dehghan, Abbas , Jackson, Anne , Kumar, Ashish , Malerba, Giovanni , Ruderfer, Douglas , Smith, Jennifer A. , Zhao, Wei , Liu, Chunyu , Group,, CHARGE Glycemic-T2D Working, Group,, CHARGE Blood Pressure Working, Campbell, Archie I , Coresh, Josef , Curhan, Gary C. , Cusi, Daniele , Denny, Joshua C. , Esko, Tõnu , Fülöp, Tibor , Gerhard, Glenn S. , Hansen, Torben , Hayward, Caroline , Hocking, Lynne J. , Hu, Frank B. , Jørgensen, Torben , Kooperberg, Charles , Launer, Lenore J. , Linneberg, Allan , Liu, Ching‐Ti , Meisinger, Christine, Metspalu, Andres , Nürnberg, Peter , Porteous, David John , Probst-Hensch, Nicole M , Psaty, Bruce M. , Raitakari, Olli Tuomas , Siscovick, David S. , Weiss, Stefan , Völker, Uwe , Teumer, Alexander , van Duijn, Cornelia M , Vasan, Ramachandran S , Smith, Albert V , Loos, Ruth J F , Li-Gao, Ruifang , Brody, Jennifer A , Padmanabhan, Sandosh , Levy, Daniel , de Vries, Aiko P J , Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767

Mayo Clinic

Journal of the American Society of Nephrology | December 5, 2016 | Volume: 28 | Issue: 3 | Pages: 981-994

10.1681/asn.2016020131 | PMID 27920155 Get It

Genome-wide association studies have identified >50 common variants associated with kidney function, but these variants do not fully explain the variation in eGFR. We performed a two-stage meta-analysis of associations between genotypes from the Illumina exome array and eGFR on the basis of serum creatinine (eGFRcrea) among participants of European ancestry from the CKDGen Consortium ( n Stage1 : 111,666; n Stage2 : 48,343). In single-variant analyses, we identified single nucleotide polymorphisms at seven new loci associated with eGFRcrea ( PPM1J , EDEM3, ACP1, SPEG, EYA4, CYP1A1 , and ATXN2L ; P Stage1 <3.7×10 −7 ), of which most were common and annotated as nonsynonymous variants. Gene-based analysis identified associations of functional rare variants in three genes with eGFRcrea, including a novel association with the SOS Ras/Rho guanine nucleotide exchange factor 2 gene, SOS2 ( P =5.4×10 −8 by sequence kernel association test). Experimental follow-up in zebrafish embryos revealed changes in glomerular gene expression and renal tubule morphology in the embryonic kidney of acp1- and sos2 -knockdowns. These developmental abnormalities associated with altered blood clearance rate and heightened prevalence of edema. This study expands the number of loci associated with kidney function and identifies novel genes with potential roles in kidney formation.
Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C
Pottel, Hans , Delanaye, Pierre , Schäeffner, Elke , Dubourg, Laurence , Melsom, Toralf , Lamb, Edmund J. , Glassock, Richard J. , Souza, V. de , Selistre, Luciano da Silva , Goffin, Karolien , Pauwels, Steven , Mariat, Christophe , Flamant, Martin , Ebert, Natalie , Turner, Stephen T. , Eriksen, Björn O. , Rule, Andrew D. , Delanaye, Pierre , Schaeffner, Elke , Selistre, Luciano , Ebert, Natalie

Mayo Clinic

Nephrology Dialysis Transplantation | November 16, 2016 | Volume: 32 | Issue: 3 | Pages: 497-507

10.1093/ndt/gfw425 | PMID 28089986 Get It

Abstract Background. We recently published and validated the new serum creatinine (Scr)-based full-age-spectrum equation (FAScrea) for estimating the glomerular filtration rate (GFR) for healthy and kidney–diseased subjects of all ages. The equation was based on the concept of normalized Scr and shows equivalent to superior prediction performance to the currently recommended equations for children, adolescents, adults and older adults. Methods. Based on an evaluation of the serum cystatin C (ScysC) distribution, we defined normalization constants for ScysC (QcysC = 0.82 mg/L for ages &lt;70 years and QcysC = 0.95 mg/L for ages ≥70 years). By replacing Scr/Qcrea in the FAScrea equation with ScysC/QcysC, or with the average of both normalized biomarkers, we obtained new ScysC-based (FAScysC) and combined Scr-/ScysC-based FAS equations (FAScombi). To validate the new FAScysC and FAScombi we collected data on measured GFR, Scr, ScysC, age, gender, height and weight from 11 different cohorts including n = 6132 unique white subjects (368 children, aged ≤18 years, 4295 adults and 1469 older adults, aged ≥70 years). Results. In children and adolescents, the new FAScysC equation showed significantly better performance [percentage of patients within 30% of mGFR (P30) = 86.1%] than the Caucasian Asian Paediatric Adult Cohort equation (P30 = 76.6%; P &lt; 0.0001), or the ScysC-based Schwartz equation (P30 = 68.8%; P &lt; 0.0001) and the FAScombi equation outperformed all equations with P30 = 92.1% (P &lt; 0.0001). In adults, the FAScysC equation (P30 = 82.6%) performed equally as well as the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPIcysC) (P30 = 80.4%) and the FAScombi equation (P30 = 89.9%) was also equal to the combined CKD-EPI equation (P30 = 88.2%). In older adults, FAScysC was superior (P30 = 88.2%) to CKD-EPIcysC (P30 = 84.4%; P &lt; 0.0001) and the FAScombi equation (P30 = 91.2%) showed significantly higher performance than the combined CKD-EPI equation (P30 = 85.6%) (P &lt; 0.0001). Conclusion. The FAS equation is not only applicable to all ages, but also for all recommended renal biomarkers and their combinations.
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Rosen, Lee S. , Algazi, Alain P. , Moser, Brian A., Hu, Tianle, Wang, Xuejing Aimee , Tuttle, Jay , Wooldridge, James E. , Banck, Michaela S., Banck, Michaela, Goldman, Jonathan W. , Turner, P. Kellie , Wacheck, Volker

Mayo Clinic

Clinical Cancer Research | October 11, 2016 | Volume: 23 | Issue: 8 | Pages: 1910-1919

10.1158/1078-0432.ccr-16-1418 | PMID 27803065 Get It

Abstract Purpose: The MET/HGF pathway regulates cell proliferation and survival and is dysregulated in multiple tumors. Emibetuzumab (LY2875358) is a bivalent antibody that inhibits HGF-dependent and HGF-independent MET signaling. Here, we report dose escalation results from the first-in-human phase I trial of emibetuzumab. Experimental Design: The study comprised a 3+3 dose escalation for emibetuzumab monotherapy (Part A) and in combination with erlotinib (Part A2). Emibetuzumab was administered i.v. every 2 weeks (Q2W) using a flat dosing scheme. The primary objective was to determine a recommended phase II dose (RPTD) range; secondary endpoints included tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Results: Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non–small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. No dose-limiting toxicities and related serious or ≥ grade 3 adverse events were observed. The most common emibetuzumab-related adverse events included mild diarrhea, nausea, and vomiting, and mild to moderate fatigue, anorexia, and hypocalcemia in combination with erlotinib. Emibetuzumab showed linear PK at doses &gt;210 mg. Three durable partial responses were observed, one for emibetuzumab (700 mg) and two for emibetuzumab + erlotinib (700 mg and 2,000 mg). Both of the responders to emibetuzumab + erlotinib had progressed to prior erlotinib and were positive for MET protein tumor expression. Conclusions: Based on tolerability, PK/PD analysis, and preliminary clinical activity, the RPTD range for emibetuzumab single agent and in combination with erlotinib is 700 to 2,000 mg i.v. Q2W. Clin Cancer Res; 23(8); 1910–9. ©2016 AACR.
Autosomal and X chromosome structural variants are associated with congenital heart defects in Turner syndrome: The NHLBI GenTAC registry
Bondy, Carolyn A., Maslen, Cheryl L. , Silberbach, Michael , Bossone, Eduardo , Citro, Rodolfo , Investigators, BAVCon Investigators, GenTAC Registry, LeMaire, Scott A. , Body, Simon C. , Prakash, Siddharth K. , Lin, Angela E. , Perrone, Laura , Limongelli, Giuseppe , Michelena, Héctor I. , Investigators, BAVCon Investigators, GenTAC Registry, Milewicz, Dianna M. , Bossone, Eduardo , Citro, Rodolfo

Mayo Clinic

American Journal of Medical Genetics Part A | September 8, 2016 | Volume: 170 | Issue: 12 | Pages: 3157-3164

10.1002/ajmg.a.37953 | PMID 27604636 Get It

Turner Syndrome (TS) is a developmental disorder caused by partial or complete loss of one sex chromosome. Bicuspid aortic valve and other left‐sided congenital heart lesions (LSL), including thoracic aortic aneurysms and acute aortic dissections, are 30–50 times more frequent in TS than in the general population. In 454 TS subjects, we found that LSL are significantly associated with reduced dosage of Xp genes and increased dosage of Xq genes. We also showed that genome‐wide copy number variation is increased in TS and identify a common copy number variant (CNV) in chromosome 12p13.31 that is associated with LSL with an odds ratio of 3.7. This CNV contains three protein‐coding genes (SLC2A3, SLC2A14, and NANOGP1) and was previously implicated in congenital heart defects in the 22q11 deletion syndrome. In addition, we identified a subset of rare and recurrent CNVs that are also enriched in non‐syndromic BAV cases. These observations support our hypothesis that X chromosome and autosomal variants affecting cardiac developmental genes may interact to cause the increased prevalence of LSL in TS. © 2016 Wiley Periodicals, Inc.
What Factors Are Predictive of Outcome in the Treatment of Soft Tissue Sarcomas of the Foot and Ankle?
Beahrs, Taylor R., Rose, Peter S. , Sim, Franklin H. , Turner, Norman S. , Wyles, Cody C. , Houdek, Matthew T.

Mayo Clinic

Foot & Ankle Specialist | September 1, 2016 | Volume: 10 | Issue: 1 | Pages: 12-19

10.1177/1938640016666925 | PMID 27587379 Get It

Soft tissue sarcomas of the foot and ankle are common. Currently, there exist limited data on prognostic variables. The aim of this study was to review our institution’s experience with soft tissue sarcomas of the foot and ankle to identify factors affecting outcomes and survivorship. We reviewed the records of 62 foot and ankle soft tissue sarcomas treated with definitive surgery at our institution between 1992 and 2013. The cohort consisted of 35 males and 27 females with a mean age at diagnosis of 45 years and a mean follow-up of 7 years. The most common tumor subtype was synovial sarcoma (n = 16). The overall limb salvage rate was 53%. Local recurrence was observed in 9 patients and distant metastases in 15 patients. Tumor size ≥3 cm in maximal dimension was the greatest risk factor in mortality. Posttreatment complications occurred in 15 patients. Local recurrence and development of distant disease was relatively common following wide excision of a soft tissue sarcoma of the foot and ankle. Tumors that were ≥3 cm in maximal dimension were associated with a worse overall survival and patients with neoadjuvant radiation were at increased risk of complications. Levels of Evidence: Level IV: Retrospective Case Series